Overview
The investigators hypothesize that the association of I-ONE® therapy with standard rehabilitation treatment can optimize the clinical and functional recovery of patients with pulsed electromagnetic fields (PEMFs) (I-ONE® therapy) of the foot or ankle.
Description
Study design; spontaneous, prospective, randomized study with control group.
Purpose of the study:
evaluate the functional clinical improvement of the foot/ankle joint with algodystrophic pathology following a standard rehabilitation treatment and home biophysical treatment and local biophysical stimulation with I-ONE® therapy (IGEA SpA).
Eligibility
Inclusion Criteria:
- Diagnosis of type I CRPS according to the Budapest criteria (table 1)
- Type I CRPS involving the ankle or foot
- Onset of CRPS type I up to a maximum of 3 years after the symptomatic event
- Pain on visual analog scale (VAS) scale quantified as intensity at least ≥ 5 at recruitment
- Pharmacological treatment with first infusion cycle of neridronate
Exclusion Criteria:
- Neurological pathologies (stroke, degenerative, traumatic pathologies)
- Local neurological impairment (type II CRPS), confirmed by a conduction test or similar
- Cardiac pacemaker, treatment site malignancy